Other

Nuvelo, Inc.

Variagenics, Inc.

Nova Molecular, Inc.

Keith Schappert

Pierre S&eacute;vigny

Heiko Wiebusch

Philippe Amouye

The invention provides methods for identifying or stratifying subjects having Alzheimer's disease or at risk for Alzheimer's disease by determining the genotype at nucleotide 172 of the PON1 allele of the subject.

Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease

The invention provides methods for treating or identifying subjects having a neurological disease or at risk for a neurological disease by determining the presence of a variant GPIIIa and/or GPIIb allele.

Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant GPIIIa and/or variant BPIIb allele

Disclosed herein is a method for treating a patient with a neurological disease by determining a patient's BCHE allele status.

Methods for treating a neurological disease by determining BCHE genotype

The present invention provides a method for the determining the prognosis for a patient diagnosed with a neurological disease. The present invention also provides a method for the identification of human subjects for placement in clinical drug trials of drugs being tested for the treatment of neurological disease and for determining a patient's future disease risk.

Growing community of inventors

Montreal, Canada

Keith Schappert